Please assess the completion status of the following clinical trial:

Trial Title: Minocycline for the Treatment of Early-Phase Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. age between 18-35 years;~2. current DSM-IV diagnosis of schizophrenia confirmed by the Structured Clinical Interview for DSM-IV (SCID) conducted by a trained psychiatrist.~3. being at an early phase of the disorder (i.e., within five years of their first exposure to neuroleptic treatment;18)~4. did not receive antipsychotic treatment for six months preceding current symptom exacerbation;~5. baseline total score of more than 60 on the Positive and Negative Syndrome Scale (PANSS).~6. Initiation of treatment with atypical antipsychotic medication equal or less than 14 days prior to study entry (risperidone, olanzapine, quetiapine, or clozapine; 200-600 mg/day chlorpromazine equivalent doses);~7. able to comprehend the procedure and aims of the study.~Exclusion Criteria:~1. acute, unstable, significant or untreated medical illness beside schizophrenia;~2. pregnant or breast-feeding females;~3. A DSM-IV diagnosis of substance abuse or dependency;~4. Known contraindication to minocycline treatment.~5. Treatment with minocycline or Beta-lactam antibiotics in the preceding half year before study entry.~6. Under compulsory hospitalization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Minocycline treatment
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).